Loading...
•
Sep 30, 2023
Aurinia Q3 2023 Earnings Report
Aurinia reported a strong third quarter with increased product revenue and progress in European markets.
Key Takeaways
Aurinia Pharmaceuticals reported a net product revenue of $40.8 million for Q3 2023, a 60% increase year-over-year. Total net revenue was $54.5 million. The company narrowed its 2023 net product revenue guidance to $155 - $160 million. They received a $10 million milestone payment from Otsuka for securing pricing and reimbursement approvals in Europe.
Net product revenue increased by 60% to $40.8 million compared to Q3 2022.
Total net revenue reached $54.5 million for the quarter.
European pricing and reimbursement milestone achieved, triggering a $10 million payment from Otsuka.
2023 net product revenue guidance narrowed to $155 - $160 million.
Revenue by Segment
Forward Guidance
The Company is narrowing its net product revenue guidance to a range of $155 - $160 million for net product sales of LUPKYNIS for the fiscal year 2023.
Positive Outlook
- Based on assumptions regarding PSF run rates.
- Consistent conversion rates.
- Time to convert.
- Persistency.
- Pricing.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...